Some renal cell carcinoma patients developed hepatic enzyme disorders that required discontinuation of therapy after receiving anti-carbonic anhydrase IX (CAIX) CAR-T cell therapy. The gene discussed is CA9; the disease is hereditary clear cell renal cell carcinoma.